SecBot SecBot
144 ·Filed Jun 29, 2026

VIR

Vir Biotechnology, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed4mo ago SEC0001959173-26-004947
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

This is a small, routine sale by a former director following an option exercise. No material impact expected. Monitor for any larger insider sales ahead of upcoming catalysts.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.38
T+0 close · Jun 29, 2026 · via day close
Latest settled
+6.84%
T+60 · $11.09
Vs SPY
+3.22%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 29 $10.38entry
  2. T+1 · 5mo ago −1.83%α −2.61% · $10.19
  3. T+5 · 4mo ago −3.47%α −4.86% · $10.02
  4. T+20 · 4mo ago −16.28%α −16.00% · $8.69
  5. T+60 · 8w ago +6.84%α +3.22% · $11.09
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Former director Saira Ramasastry filed a Form 144 on June 29, 2026, indicating intent to sell 16,000 shares of Vir Biotechnology (VIR) with an approximate market value of $165,139. The sale follows a stock option exercise and represents a routine diversification move by a former board member, not a current executive. Given the small size relative to VIR's $1.7B market cap and the insider's former-director status, the signal is minimal.

Key Facts

  • Insider: Saira Ramasastry, former director
  • Shares to be sold: 16,000 shares of common stock
  • Estimated value: ~$165,139
  • Source of shares: stock option exercise (issuer grant)
  • Broker: Fidelity Brokerage Services LLC
  • Filing date: June 29, 2026

Financial Impact

Sale of 16,000 shares valued at ~$165K, representing less than 0.01% of VIR's $1.7B market cap

dilution

Risk Factors

  • Insider selling could increase if more directors or executives file similar notices
  • Option exercise may signal limited upside conviction from this insider

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
93% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001959173-26-004947
Document: 0001959173-26-004947-index.html0001959173-26-004947
Document: 0001959173-26-004947.txt0001959173-26-004947

Track record

36 reports on VIR

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
  2. Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
  3. Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
  4. Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
  5. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
  6. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
  7. Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
  8. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
  10. Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens Wed (9h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 29, 2026